Retatrutide vs Cagrilintide Cost Comparison

A retatrutide vs cagrilintide cost comparison has to separate two questions that listings often blur together: what a vial costs as a whole, and what that works out to per milligram once vial size is accounted for. Retatrutide, a triple-receptor agonist, and cagrilintide, an amylin analog, are frequently listed side by side on the same supplier catalogues, but they are structurally different compounds with independent pricing, so a lower sticker price on one does not automatically mean a better per-mg rate. The only way to compare them meaningfully is to normalize both to the same unit before drawing any conclusion.

How Retatrutide and Cagrilintide Pricing Structures Differ

Retatrutide listings tend to span a wider range of vial sizes, reflecting its longer presence on research-supplier catalogues and the broader spread of mg amounts sellers stock. Cagrilintide listings, by contrast, are often concentrated around a narrower band of vial sizes, since it entered supplier catalogues more recently and inventory has not diversified as much. Neither pattern says anything about which compound is “cheaper” — it just means the two are usually compared at different vial sizes, which makes per-mg normalization the only fair basis for a retatrutide vs cagrilintide cost comparison.

Total vial price is also a function of factors that have nothing to do with the compound itself: packaging, shipping tier, and a supplier’s general markup structure all sit on top of the base cost. Two suppliers selling the same compound at the same mg amount can post different sticker prices purely because of these fixed costs, which is why a single-listing snapshot is a weak basis for comparison and a per-mg figure across multiple listings is a stronger one.

Worked Example: Comparing Per-mg Cost

Suppose a listing prices a 10mg retatrutide vial at $160, and a 10mg cagrilintide vial from the same supplier at $130.

Retatrutide: $160 / 10mg = $16.00 per mg Cagrilintide: $130 / 10mg = $13.00 per mg

At matched vial size, cagrilintide comes out lower per mg in this example. But vial sizes are not always matched across a supplier’s catalogue. Suppose a second supplier lists a 5mg retatrutide vial at $95 and a 5mg cagrilintide vial at $80.

Retatrutide: $95 / 5mg = $19.00 per mg Cagrilintide: $80 / 5mg = $16.00 per mg

The per-mg gap widens at the smaller vial size in this second example, which illustrates why a single comparison at one vial size does not generalize to a supplier’s full catalogue. Each pairing has to be recalculated independently rather than assumed to hold across sizes.

Cost Comparison Table

Comparison Point	Retatrutide	Cagrilintide
Common vial sizes seen in listings	Wider range (small to large)	Narrower range, fewer size tiers
Example: 10mg vial price	$160	$130
Example: 10mg per-mg cost	$16.00/mg	$13.00/mg
Example: 5mg vial price	$95	$80
Example: 5mg per-mg cost	$19.00/mg	$16.00/mg
Price driver beyond compound	Packaging, shipping tier, markup	Packaging, shipping tier, markup

The figures in this table are worked examples built to demonstrate the per-mg calculation, not fixed market prices — actual listings vary by supplier and change over time, so the formula matters more than any specific number in the table.

Why Vial Size and Concentration Complicate Comparisons

Vial size affects total price but not concentration on its own — concentration depends on how much bacteriostatic water gets added during reconstitution. A 10mg vial reconstituted with 2mL of bacteriostatic water sits at a concentration of 5mg/mL (10mg ÷ 2mL). On a U-100 insulin syringe, where 1mL equals 100 units, each unit at that concentration corresponds to 0.05mg, or 50mcg. That relationship between concentration and syringe markings is a separate calculation from cost, but the two get evaluated together in practice, because a buyer comparing retatrutide and cagrilintide listings is usually also comparing how each vial’s concentration will read on the same syringe scale.

This is also where documentation quality becomes relevant to a cost comparison rather than a side issue. A listing that provides a certificate of analysis alongside its price gives a buyer a way to confirm the mg amount used in a per-mg calculation actually matches vial contents, rather than trusting a label figure alone — background on how retatrutide sourcing and documentation standards are typically structured is covered in more detail by HEEZ Research. Cagrilintide listings should be held to the same documentation standard before their price gets folded into a comparison.

Reconstitution volume itself does not change what a vial costs — it only redistributes the same fixed mg amount across a different liquid volume. A retatrutide vial reconstituted with more diluent produces a lower concentration at the same total cost; the same is true for a cagrilintide vial. Readers running this math alongside a cost comparison can check concentration figures independently using a general-purpose reconstitution calculator such as peptcalc.com.

Reading Listings for Both Compounds Correctly

Some suppliers list retatrutide and cagrilintide with per-vial price as the primary figure and mg content in smaller text below it; others lead with per-mg pricing directly. When running a retatrutide vs cagrilintide cost comparison across several suppliers, it helps to convert every listing to the same per-mg unit before lining them up, since two listings with similar sticker prices can represent very different per-mg rates once vial size is accounted for.

Bundled or multi-vial listings add a further variable. A three-pack of cagrilintide vials priced as a set needs its total price divided across both vial count and mg-per-vial to produce a comparable per-mg figure — dividing the bundle price by a single vial’s mg amount understates the true per-mg cost. The same applies to any multi-vial retatrutide bundle. Normalizing to total price divided by total mg across the full bundle keeps the comparison consistent with the single-vial examples above.

Summary

A retatrutide vs cagrilintide cost comparison only holds up when both compounds are normalized to a per-mg basis, since the two are typically stocked in different vial-size ranges and a raw sticker-price comparison does not account for that. The per-mg formula — vial price divided by vial mg content — stays the same regardless of which compound is being priced, but it has to be recalculated for each specific listing rather than assumed from one example. Reconstitution volume changes concentration, not cost, so it remains a separate step from the pricing math, and documentation quality is worth checking before either compound’s mg figure gets treated as reliable input for a comparison.